Navigation Links
ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting
Date:10/27/2010

MOUNTAIN VIEW, Calif., Oct. 27 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it reported one-year results from the Company's PROTECT-1 Study (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN™ (CCX282-B) in patients with moderate-to-severe Crohn's disease. Traficet-EN, an orally bioavailable CCR9-specific chemokine receptor antagonist showed clinical efficacy in a 12-week Induction period, as well as a 36-week Maintenance period. Specifically, Traficet-EN demonstrated evidence of clinical efficacy in the reduction of disease activity as defined by a 70-point or 100-point decrease in the Crohn's Disease Activity Index (CDAI) during the Induction period.  Furthermore, approximately 50% of patients receiving Traficet-EN in the Maintenance period were in clinical remission (CDAI less than 150) by the end of the 36 weeks compared to 31% of patients receiving placebo.  Traficet-EN continued to be safe and well tolerated.  Phase III clinical trials designed to evaluate Traficet-EN in patients with moderate-to-severe Crohn's disease are expected to initiate before the end of the year.  

Additionally, conclusive evidence was provided that the involvement of CCR9 and its chemokine ligand (TECK) in inflammatory bowel disease (IBD) is not just restricted to the small bowel, but is relevant to inflammation of the large bowel as well.  These findings as well as the Traficet-EN one-year study results were highlighted at the 18th United European Gastroenterology Federation (UEGW) meeting in Barcelona, Spain in a poster presentation entitled "One-Year Results from PROTECT-1 Study of Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease" and in an oral presentation entitled "CCR9 Inhibition in the Treatment of Colonic Inflammation" presented by Dr. Juan C. Jaen, Senior Vice President, Drug Discovery and Chief Scientific Officer, ChemoCentryx, Inc.


'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
2. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
3. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
4. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
5. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
8. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
9. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
10. Mylan Reports Adjusted Diluted EPS of $0.43; Reaffirms 2010 Adjusted Diluted EPS Guidance of $1.55 - $1.65
11. Abaxis Reports Financial Performance with Record Sales for the Second Quarter of Fiscal 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 Consolidated Net Profit increased ... Highlights   , India Business grew by 20.87% ... to Rs. 4,886.70 Mn Rest of World (ROW) Business ... Business grew by 34.53% to Rs. 977.26 Mn Latin ... Glenmark Pharmaceuticals Limited, the research-led global integrated pharmaceutical ...
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- Delivery ... once order is placed. Photo - ... a professional and in-depth market survey on Global ... reviews the basic information of Hemodialysis Machine including ... then explores global and China,s top manufacturers of ...
(Date:7/24/2014)... Scotland , July 24, 2014 Cancer patients ... gain access to state-of-the-art cancer treatment closer to home when ... next year. Varian Medical Systems (NYSE: VAR ... an order was placed in June for four TrueBeam™ medical ... systems, which offer fast and efficient radiotherapy and radiosurgery treatments, ...
Breaking Medicine Technology:Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 2Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 3
... Incorporated (Nasdaq: ARAY ), the premier radiation oncology ... Euan S. Thomson, Ph.D., is scheduled to present at the ... City on Tuesday November 15, 2011 at 10:30 a.m. EST/7:30 ... the Stephens Fall Investment Conference in New York City on ...
... PARSIPPANY, N.J., Nov. 10, 2011 Columbia Laboratories, Inc. ... (NYSE: WPI ), today confirmed that the ... Food and Drug Administration (FDA) is scheduled to review ... for the reduction of risk of preterm birth in ...
Cached Medicine Technology:Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 2Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 3Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 4
(Date:7/24/2014)... CO (PRWEB) July 24, 2014 This year ... by E Light Electric and Jackson National Life, will be ... begins at 7 am, the Kids Fun Run at 7:50 ... Walk starts at 9 a.m. , “The Walk to End ... strength and dedication in the fight against this devastating disease, ...
(Date:7/24/2014)... like a medical device or surgical implant is put ... to Northwestern University,s Guillermo Ameer, most of the time, ... function. , "You will always get an inflammatory response ... in Northwestern,s McCormick School of Engineering and Applied Science ... Medicine. "A problem with commonly used plastic materials, in ...
(Date:7/24/2014)... Children,s Hospital and the University of Tennessee Health Science ... new drug shown to safely reduce the viral load ... with respiratory syncytial virus (RSV). RSV is the most ... children in the United States and worldwide. , ... Specialist John DeVincenzo, MD. DeVincenzo,s Le Bonheur lab has ...
(Date:7/24/2014)... Atlanta, GA (PRWEB) July 24, 2014 ... Act on Tuesday, President Obama cited the Atlanta ... 35 model programs from across the country ( ... training as an essential pillar of U.S. economic ... replicated nationally. , “This recognition from President Obama ...
(Date:7/24/2014)... scientists at Carnegie Mellon University, working with high-throughput ... Berkeley National Laboratory, have devised a computational method ... normal breast cells turn malignant and as they ... for analyzing how genes interact with each other ... published today by the online journal PLOS ...
Breaking Medicine News(10 mins):Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 2Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 3Health News:Antioxidant biomaterial promotes healing 2Health News:RSV research breakthrough to help infected children 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 4Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 5Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3
... Reporter , MONDAY, Sept. 27 (HealthDay News) -- There ... other noncarbonated beverages are associated with physical activity they ... In a study of more than 15,000 middle and ... who drank sugar-sweetened beverages, including sports drinks, were more ...
... Nearly 500 researchers, clinicians and mental health advocates ... Conference, Perinatal Mental Health Research: Harvesting the Potential, Oct. ... in Pittsburgh. The event, which focuses on women,s mental ... former First Lady Rosalynn Carter, who has been an ...
... Reinberg HealthDay Reporter , SATURDAY, Sept. 25 ... not drinking as much water as they should, and ... suggests. "Even mild dehydration can affect physiological function, ... said Samantha Heller, clinical nutrition coordinator at the Center ...
... to arrest the growth and spread of tumors, there have ... internal instruction manual. In a new study, a team ... molecule able to prevent cancer genes from "hearing" those instructions, ... published online by the journal Nature , demonstrates that ...
... Steven Reinberg HealthDay Reporter , THURSDAY, Sept. ... about heart risks, U.S. health officials on Thursday severely ... patients with type 2 diabetes who cannot control their ... Administration officials also ordered the drug,s manufacturer, GlaxoSmithKline, to ...
... and GLG Pharma, LLC announced today that they have ... LLC has acquired the exclusive worldwide rights to a ... Researchers at Moffitt discovered several classes of STAT3 ... drugs. "Persistently activated STAT3 is a major ...
Cached Medicine News:Health News:Study Finds Teens Think Sports Drinks Are Healthy 2Health News:Study Finds Teens Think Sports Drinks Are Healthy 3Health News:U.S. Kids Drink Too Little Water: Study 2Health News:U.S. Kids Drink Too Little Water: Study 3Health News:Researchers create first molecule blocks key component of cancer genes' on-off switch 2Health News:Researchers create first molecule blocks key component of cancer genes' on-off switch 3Health News:FDA Restricts Access to Avandia 2Health News:FDA Restricts Access to Avandia 3
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... glucose monitor elevates bedside glucose testing to ... approaches the quality of central laboratory testing. ... measuring strip technology. Current glucose strips ... Multi-Well system measures and corrects hematocrit interference ...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... The BreatheX is a wearable CPAP ... treatment of sleep apnea. The lightweight BreatheX ... of therapy with its built-in, rechargeable battery, ... users will no longer need to be ...
Medicine Products: